A recent study suggests that patients who stop using popular weight-loss injections like semaglutide or tirzepatide can put back on shed pounds far faster than those who end traditional lifestyle regimens.
Research printed in a leading medical journal demonstrates that while overweight people frequently drop substantial amounts of their body weight while using the jabs, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"Users using these treatments need to be cognizant of the potential of fast weight regain when the therapy ends," warns expert Dr. Susan Jebb.
This pace of regain suggests a reversion to original mass within about one and a half years.
Weighing Approaches
The research, which examined 37 of studies involving over 9,000 of patients, compared the outcomes of these new drugs with older methods.
Scientists point out that people who lose weight through lifestyle changes alone usually experience a less rapid creep back—perhaps 100 grams monthly—after stopping.
Understanding the Quick Rebound
Experts propose the mechanism of the drugs accounts for the amplified regain.
The injections imitate a natural hormone called GLP-1, which helps regulate appetite.
"Sustained high doses of the hormone concentrations several times higher than the body's typical production may cause the body to produce less of its endogenous hormone, and could diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication leads to appetite is uncontrolled, making excessive eating much more probable."
A Chronic Disease?
Health authorities advise the jabs for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, considering the likelihood of weight regain, the treatment should be considered life-long.
This perspective is reinforced by pharmaceutical companies, who state that the results "underscore the long-term nature of obesity," akin to managing diseases like high blood pressure.
Patient Accounts
Users who have stopped the medication describe a powerful resurgence of cravings.
"It was like a switch that goes on and you're instantly starving," said a patient.
This challenge is exacerbated if users have not adopted permanent dietary or behavioural modifications during treatment.
Growing Adoption
Survey data suggest that a significant number of people in the UK have tried these injections in the last 12 months, with interest remaining high.
- Adoption is more common among women than men.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
Ultimately, researchers stress that while GLP-1 drugs are powerful agents for shedding pounds, they are not a permanent fix and lasting health benefits hinges on integrated behavioural support.
